Aphios
Corporation Presents “Manufacturing Safe Nanomedicines”
at BIT's
1st Annual World Congress of NanoMedicine 2010 in Beijing,
China
October
24 , 2010
— We
use “green” SuperFluids™ (supercritical
fluids, critical or near-critical fluids with and without
polar cosolvents such as ethanol) which are nontoxic and
environmentally benign in combination with generally regarded
as safe (GRAS) biodegradable nanomaterials to manufacture
safe nanomedicines.
SuperFluids™
[SFS] are utilized phospholipid nanosomes, which are small,
uniform liposomes by our SFS-CFN process. Phospholipid nanosomes
are nanometer-sized vesicles of phospholipid bilayers comprised
of single or multiple lipid bilayers. As such, they are
non-toxic, non-antigenic and biodegradable in character
since they have the molecular characteristics of mammalian
cell membranes. Hydrophilic compounds and therapeutics such
as recombinant proteins and siRNA are encapsulated in the
aqueous core while hydrophobic compounds and therapeutics
such as anticancer and other water-insoluble drugs are trapped
within the lipid bilayers. Encapsulation masks the hydrophobic
(water-insoluble) nature of drugs, and permits aqueous,
biocompatible formulations to be administered. Phospholipid
nanosomes protect the encapsulated therapeutics prolonging
their circulation and increasing half-life. For cancer chemotherapy,
this increases the likelihood that the drug will reach and
destroy cancer cells. Encapsulation also protects cells
from the circulating therapeutics and reduces their toxicities.
SuperFluids™
are also utilized to manufacture polymer nanospheres comprising
of hydrophobic biodegradable copolymers by our SFS-PNS process.
These nanospheres can be used for the oral delivery of therapeutic
proteins such as insulin, hydrophobic anticancer drugs and
small molecules as well as the controlled release of viral
(HIV and influenza) and bacterial (anthrax) antigens for
vaccines.
SuperFluids™
are also utilized to make protein nanoparticles by our SFS-PNP
process. Protein nanoparticles can be utilized for the pulmonary
delivery of protein therapeutics or in biodegradable polymer
microspheres/nanospheres for controlled release depot or
oral delivery. With proteinaceous therapeutics, the generation
of nanoparticles is particularly problematic. Existing practices
have difficulty achieving the desired particle size distribution,
expose the protein to denaturing conditions such as heat,
organic solvents or air and often require stabilizing excipients
or leave residual product contamination that necessitates
further processing. Our process uses SuperFluids™
to penetrate the protein aggregates and then its expansive
energy to disaggregate protein crystals into monodisperse
nanoparticles without loss of bioactivity and no residual
contamination to make a safe nanomedicine.
###
